This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 87.6% upside potential for Celcuity (CELC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Celcuity (CELC) Upgraded to Buy: Here's Why
by Zacks Equity Research
Celcuity (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Celcuity (CELC) Might Surprise This Earnings Season
by Zacks Equity Research
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Celcuity, Inc. (CELC) points to a 359.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 461.9% in Celcuity, Inc. (CELC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Celcuity, Inc. (CELC) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Celcuity, Inc. (CELC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Celcuity's (CELC) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Celcuity Inc. (CELC).
Company News for Apr 12, 2021
by Zacks Equity Research
Companies in the news are: AFMD, FUBO, GENE, CELC
Celcuity (CELC) Soars on Agreement With Pfizer & Study Data
by Zacks Equity Research
Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.
Company News for Mar 18, 2021
by Zacks Equity Research
Companies in the news are: LE, SMTC, CRAWA, CELC
The Zacks Analyst Blog Highlights: Red Robin, Celcuity, Atlas Air and Boston Private
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Red Robin, Celcuity, Atlas Air and Boston Private
4 Small Cap Stocks to Get Rid of Before Entering 2020
by Nikita Kataruka
While domestic economic growth has been benefiting small-cap stocks until now, you should consider selling some of the stocks before entering 2020 because of poor earnings growth projections.
All You Need to Know About Celcuity, Inc. (CELC) Rating Upgrade to Buy
by Zacks Equity Research
Celcuity, Inc. (CELC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Paratek Pharmaceuticals (PRTK) Catches Eye: Stock Jumps 10.2%
by Zacks Equity Research
Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review
by Zacks Equity Research
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4
by Zacks Equity Research
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
Celcuity, Inc. (CELC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Celcuity, Inc. (CELC) a New Strong Buy Stock
by Zacks Equity Research
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Celcuity, Inc. (CELC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Autolus Therapeutics (AUTL) Catches Eye: Stock Jumps 5.6%
by Zacks Equity Research
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
InflaRx (IFRX) Catches Eye: Stock Jumps 7.5%
by Zacks Equity Research
InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Nabriva Therapeutics (NBRV) in Focus: Stock Moves 7.5% Higher
by Zacks Equity Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Krystal (KRYS) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Krystal (KRYS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.